KR102475124B1 - sGC 자극제를 사용한 CNS 질환의 치료 - Google Patents

sGC 자극제를 사용한 CNS 질환의 치료 Download PDF

Info

Publication number
KR102475124B1
KR102475124B1 KR1020197016351A KR20197016351A KR102475124B1 KR 102475124 B1 KR102475124 B1 KR 102475124B1 KR 1020197016351 A KR1020197016351 A KR 1020197016351A KR 20197016351 A KR20197016351 A KR 20197016351A KR 102475124 B1 KR102475124 B1 KR 102475124B1
Authority
KR
South Korea
Prior art keywords
disorder
cns
disease
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016351A
Other languages
English (en)
Korean (ko)
Other versions
KR20190094167A (ko
Inventor
준 정
토마스 와이-호 리
라제쉬 알. 아이옌가
니콜라스 로버트 펄
피터 게르마노
마리아 디. 리바데네이라
킴 탕
Original Assignee
사이클리온 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이클리온 테라퓨틱스, 인크. filed Critical 사이클리온 테라퓨틱스, 인크.
Publication of KR20190094167A publication Critical patent/KR20190094167A/ko
Application granted granted Critical
Publication of KR102475124B1 publication Critical patent/KR102475124B1/ko
Assigned to 티센토 쎄라퓨틱스 인크. reassignment 티센토 쎄라퓨틱스 인크. 권리의 전부이전등록 Assignors: 사이클리온 테라퓨틱스, 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197016351A 2016-11-08 2017-11-07 sGC 자극제를 사용한 CNS 질환의 치료 Active KR102475124B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
US62/419,059 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Publications (2)

Publication Number Publication Date
KR20190094167A KR20190094167A (ko) 2019-08-12
KR102475124B1 true KR102475124B1 (ko) 2022-12-08

Family

ID=60452769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016351A Active KR102475124B1 (ko) 2016-11-08 2017-11-07 sGC 자극제를 사용한 CNS 질환의 치료

Country Status (18)

Country Link
US (4) US11690828B2 (https=)
EP (1) EP3538096B1 (https=)
JP (2) JP7150740B2 (https=)
KR (1) KR102475124B1 (https=)
CN (1) CN110267658B (https=)
AU (2) AU2017359018C1 (https=)
BR (1) BR112019009449A2 (https=)
CA (1) CA3042548A1 (https=)
CL (1) CL2019001256A1 (https=)
EA (1) EA201991147A1 (https=)
ES (1) ES2972711T3 (https=)
IL (1) IL266275B2 (https=)
MA (1) MA46752A (https=)
MX (2) MX2019005342A (https=)
PH (1) PH12019501016A1 (https=)
SG (1) SG10202104865UA (https=)
TW (1) TWI812601B (https=)
WO (1) WO2018089328A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180493B2 (en) * 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
KR20210031931A (ko) 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
CN114929207A (zh) * 2019-12-05 2022-08-19 载度思生命科学有限公司 利奥西呱的调节释放型药物组合物
WO2021158059A1 (ko) 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
TW202308634A (zh) * 2021-04-20 2023-03-01 美商賽克瑞恩醫療公司 使用sGC刺激劑之CNS疾病治療
EP4456897A4 (en) * 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
KR20250160137A (ko) * 2023-02-03 2025-11-11 알.피.쉐러 테크놀러지즈 엘엘씨 삼투압 약학적 캡슐

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004235A1 (en) 2006-04-27 2010-01-07 Bayer Healthcare Ag Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1653926A1 (en) 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2016371762A1 (en) * 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
CR20220309A (es) * 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004235A1 (en) 2006-04-27 2010-01-07 Bayer Healthcare Ag Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 21(21), 6515-6518, 2011.*
Future Med. Chem., 5(12), 1451-1468, 2013.

Also Published As

Publication number Publication date
AU2023270267A1 (en) 2023-12-07
EP3538096C0 (en) 2024-02-28
CL2019001256A1 (es) 2019-10-04
US11690828B2 (en) 2023-07-04
US20230381153A1 (en) 2023-11-30
IL266275B2 (en) 2023-12-01
NZ753434A (en) 2025-10-31
TW201822765A (zh) 2018-07-01
AU2017359018A1 (en) 2019-05-30
KR20190094167A (ko) 2019-08-12
MX2019005342A (es) 2019-10-02
BR112019009449A2 (pt) 2019-07-30
EA201991147A1 (ru) 2019-11-29
TWI812601B (zh) 2023-08-21
US20250108040A1 (en) 2025-04-03
JP7150740B2 (ja) 2022-10-11
EP3538096A1 (en) 2019-09-18
IL266275B1 (en) 2023-08-01
JP2022160605A (ja) 2022-10-19
AU2017359018B2 (en) 2023-08-31
AU2017359018C1 (en) 2023-12-21
IL266275A (en) 2019-06-30
MX2022010852A (es) 2022-09-27
PH12019501016A1 (en) 2019-09-09
MA46752A (fr) 2019-09-18
SG10202104865UA (en) 2021-06-29
JP2019534327A (ja) 2019-11-28
EP3538096B1 (en) 2024-02-28
US20190343813A1 (en) 2019-11-14
WO2018089328A1 (en) 2018-05-17
ES2972711T3 (es) 2024-06-14
CN110267658B (zh) 2024-02-02
CA3042548A1 (en) 2018-05-17
CN110267658A (zh) 2019-09-20
US20260000653A1 (en) 2026-01-01
WO2018089328A8 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
JP7628096B2 (ja) 縮合二環式ｓｇｃ刺激剤
KR102475124B1 (ko) sGC 자극제를 사용한 CNS 질환의 치료
US20240132528A1 (en) Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators
HK40013531A (en) Treatment of cns diseases with sgc stimulators
HK40013531B (en) Treatment of cns diseases with sgc stimulators
HK40061428B (en) Fused bicyclic sgc stimulators
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
BR112019004468B1 (pt) Estimulantes de sgc

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190607

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220302

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220602

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220901

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221205

End annual number: 3

Start annual number: 1

PG1601 Publication of registration